ATE440108T1 - Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilis - Google Patents
Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilisInfo
- Publication number
- ATE440108T1 ATE440108T1 AT99918966T AT99918966T ATE440108T1 AT E440108 T1 ATE440108 T1 AT E440108T1 AT 99918966 T AT99918966 T AT 99918966T AT 99918966 T AT99918966 T AT 99918966T AT E440108 T1 ATE440108 T1 AT E440108T1
- Authority
- AT
- Austria
- Prior art keywords
- textilis
- inhibitors
- pseudonaja
- brown snake
- plasmin
- Prior art date
Links
- 241000427953 Pseudonaja textilis textilis Species 0.000 title abstract 2
- 241001074017 Storeria dekayi Species 0.000 title abstract 2
- 239000002806 plasmin inhibitor Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP3450A AUPP345098A0 (en) | 1998-05-11 | 1998-05-11 | Novel anti-fibrinolytic agents |
| PCT/AU1999/000343 WO1999058569A1 (en) | 1998-05-11 | 1999-05-07 | PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440108T1 true ATE440108T1 (de) | 2009-09-15 |
Family
ID=3807704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99918966T ATE440108T1 (de) | 1998-05-11 | 1999-05-07 | Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7070969B1 (enExample) |
| EP (1) | EP1078003B1 (enExample) |
| JP (1) | JP4542705B2 (enExample) |
| AT (1) | ATE440108T1 (enExample) |
| AU (1) | AUPP345098A0 (enExample) |
| CA (1) | CA2328431C (enExample) |
| DE (1) | DE69941292D1 (enExample) |
| DK (1) | DK1078003T3 (enExample) |
| ES (1) | ES2332249T3 (enExample) |
| NZ (1) | NZ508770A (enExample) |
| WO (1) | WO1999058569A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP345098A0 (en) * | 1998-05-11 | 1998-06-04 | National Institute Of Biological Standards And Control, United Kingdom | Novel anti-fibrinolytic agents |
| US6506365B1 (en) * | 2000-09-25 | 2003-01-14 | Baxter Aktiengesellschaft | Fibrin/fibrinogen binding conjugate |
| US7745192B2 (en) * | 2002-04-03 | 2010-06-29 | Venomics Pty Limited | Prothrombin activating protein |
| PT1976985E (pt) | 2005-12-29 | 2013-10-24 | Univ California | Métodos e composições relacionados com o domínio 1 mutante de kunitz do tfpi-2 |
| EP2154152A1 (en) * | 2008-08-08 | 2010-02-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion |
| EP2359852A4 (en) * | 2008-11-17 | 2015-05-20 | Nat Cancer Ct | NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND |
| CN102850451B (zh) * | 2011-06-29 | 2014-05-07 | 辽宁诺康生物制药有限责任公司 | 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342830A (en) * | 1990-11-16 | 1994-08-30 | Cor Therapeutics, Inc. | Antithrombosis agents |
| EP0585504A1 (en) * | 1992-09-04 | 1994-03-09 | Pentapharm A.G. | Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing |
| AUPP076797A0 (en) * | 1997-12-05 | 1998-01-08 | Active (Pla) R&D Pty Ltd | Phospholipase inhibitor |
| AUPP345098A0 (en) * | 1998-05-11 | 1998-06-04 | National Institute Of Biological Standards And Control, United Kingdom | Novel anti-fibrinolytic agents |
-
1998
- 1998-05-11 AU AUPP3450A patent/AUPP345098A0/en not_active Abandoned
-
1999
- 1999-05-07 DE DE69941292T patent/DE69941292D1/de not_active Expired - Lifetime
- 1999-05-07 JP JP2000548371A patent/JP4542705B2/ja not_active Expired - Fee Related
- 1999-05-07 WO PCT/AU1999/000343 patent/WO1999058569A1/en not_active Ceased
- 1999-05-07 US US09/700,179 patent/US7070969B1/en not_active Expired - Lifetime
- 1999-05-07 AT AT99918966T patent/ATE440108T1/de not_active IP Right Cessation
- 1999-05-07 ES ES99918966T patent/ES2332249T3/es not_active Expired - Lifetime
- 1999-05-07 NZ NZ508770A patent/NZ508770A/en unknown
- 1999-05-07 DK DK99918966T patent/DK1078003T3/da active
- 1999-05-07 CA CA2328431A patent/CA2328431C/en not_active Expired - Fee Related
- 1999-05-07 EP EP99918966A patent/EP1078003B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1078003B1 (en) | 2009-08-19 |
| EP1078003A1 (en) | 2001-02-28 |
| JP2002514404A (ja) | 2002-05-21 |
| EP1078003A4 (en) | 2004-08-25 |
| DE69941292D1 (de) | 2009-10-01 |
| AUPP345098A0 (en) | 1998-06-04 |
| CA2328431A1 (en) | 1999-11-18 |
| US7070969B1 (en) | 2006-07-04 |
| JP4542705B2 (ja) | 2010-09-15 |
| NZ508770A (en) | 2003-12-19 |
| DK1078003T3 (da) | 2009-12-07 |
| WO1999058569A1 (en) | 1999-11-18 |
| CA2328431C (en) | 2010-04-27 |
| ES2332249T3 (es) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013200A (pt) | Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos | |
| NO995544D0 (no) | Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1 | |
| DE69905476D1 (en) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
| PT966465E (pt) | Inibidores do enzima imfdh | |
| BR9909242A (pt) | Inibidores de fosfolipase a2 | |
| DE69928655D1 (de) | Substituierte porphyrine | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| TR200200068T2 (tr) | Nematisital triflüorobütenler | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| TR200003159T2 (tr) | Antipicornaviral bileşikler, hazırlanışları ve kullanımları | |
| MXPA05012812A (es) | Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp). | |
| DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
| MXPA03001463A (es) | Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen. | |
| ATE250574T1 (de) | Neue verbindungen | |
| ES2088128T3 (es) | Aminosulfonilureas inhibidoras de acat. | |
| SE9804313D0 (sv) | New compounds | |
| DE60329326D1 (de) | Tace inhibitoren | |
| DE69941292D1 (de) | Schlange, pseudonaja textilis textilis | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
| NO20002408L (no) | 5-HT1F antagonister | |
| DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
| DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
| NO20054346L (no) | Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |